|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-6-25
|
|
pubmed:abstractText |
New treatments that inhibit the cytokines tumour necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1) in the treatment of rheumatoid arthritis have proven clinical effect against placebo and methotrexate (MTX) in several clinical trials in early and late-stage disease and different severity groups. Since there are no head-to-head randomized controlled trials directly comparing the currently available treatments, etanercept, adalimumab, infliximab or anakinra, we perform a meta-analysis that adjusts for differences between study characteristics, and allows indirect comparisons between treatments.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin 1 Receptor Antagonist...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1462-0324
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1140-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17478472-Antibodies, Monoclonal,
pubmed-meshheading:17478472-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17478472-Arthritis, Rheumatoid,
pubmed-meshheading:17478472-Drug Therapy, Combination,
pubmed-meshheading:17478472-Humans,
pubmed-meshheading:17478472-Immunoglobulin G,
pubmed-meshheading:17478472-Immunosuppressive Agents,
pubmed-meshheading:17478472-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:17478472-Interleukin-1,
pubmed-meshheading:17478472-Methotrexate,
pubmed-meshheading:17478472-Randomized Controlled Trials as Topic,
pubmed-meshheading:17478472-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:17478472-Treatment Outcome,
pubmed-meshheading:17478472-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
|
|
pubmed:affiliation |
MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK. richard.nixon@mrc-bsu.cam.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
